Chimerix, Inc.

For Q3 2024, Chimerix reported a net loss of $22.9 million versus a net loss of $24 million in Q3 2023. Research and development expense was $19.6 million, up from $17.4 million year over year, driven mainly by ACTION study spending. General and administrative expense was $5.2 million, down from $9.3 million a year ago, due to the absence of a one-time non-cash expense related to historical grants recorded in 2023. Cash and cash equivalents ended at just over $152 million, and management said cash runway extends into the fourth quarter of 2026. No quarterly revenue was reported on the call. Management did not provide formal next-quarter or full-year financial guidance; instead, it highlighted preparation for a year-end Australia NDA filing, potential first ACTION interim data within less than a year, and continued commercialization readiness.

Mike Andriole emphasized execution across the pipeline, especially continued enrollment in the global Phase 3 ACTION study and near completion of ONC206 dose escalation. He framed the no-change safety review as an important milestone that supports Dordaviprone’s monotherapy and backbone-therapy potential. His tone was constructive and forward-looking, stressing preparation for commercialization, broad investigator enthusiasm, and a potential global market opportunity of over $750 million.

Michelle LaSpaluto focused on the quarter’s financial profile and liquidity. She said the net loss was $22.9 million, R&D rose to $19.6 million on higher ACTION spend, and G&A fell to $5.2 million because of a one-time non-cash grant-related expense in the prior-year period. She also said the company ended with just over $152 million in cash and cash equivalents, noted a modest increase in cash burn, and stated that runway extends into Q4 2026 while the company remains committed to sensible cash management.

The main analyst questions centered on how Chimerix is preparing the Australia NDA and whether that work could support U.S. and other regulatory paths, plus how the company is building commercial infrastructure ahead of possible launch. Management said the Australia NDA backbone has utility across other markets, the efficacy package will rely on previously announced Phase 2 response rate data, and ACTION remains the first opportunity for registration elsewhere unless that changes. On commercialization, Tom Riga said the team is focused on payer engagement, forecast confirmation, and commercial build, while keeping spending gated and conservative until more data are available. A second set of questions addressed TEMBEXA: management said BARDA exercised a partial option of just over $67 million, with Chimerix due approximately $2.7 million upon receipt of cash, and noted that any monkeypox-related royalties would depend on future international sales and remain very early-stage.